KR19990082024A - 암 화학민감화에서 화학요법제와 함께 사용하기 위한 약제 제조에서의 텍사피린의 용도 - Google Patents

암 화학민감화에서 화학요법제와 함께 사용하기 위한 약제 제조에서의 텍사피린의 용도

Info

Publication number
KR19990082024A
KR19990082024A KR1019980705744A KR19980705744A KR19990082024A KR 19990082024 A KR19990082024 A KR 19990082024A KR 1019980705744 A KR1019980705744 A KR 1019980705744A KR 19980705744 A KR19980705744 A KR 19980705744A KR 19990082024 A KR19990082024 A KR 19990082024A
Authority
KR
South Korea
Prior art keywords
texaphyrin
iii
metal cation
chemotherapeutic agent
site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019980705744A
Other languages
English (en)
Korean (ko)
Inventor
리차드 에이. 밀러
스튜어트 더블유. 영
Original Assignee
다우 윌리엄스 씨.
파마사이클릭스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다우 윌리엄스 씨., 파마사이클릭스, 인코포레이티드 filed Critical 다우 윌리엄스 씨.
Publication of KR19990082024A publication Critical patent/KR19990082024A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1019980705744A 1996-01-25 1997-01-23 암 화학민감화에서 화학요법제와 함께 사용하기 위한 약제 제조에서의 텍사피린의 용도 Ceased KR19990082024A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8/591,318 1996-01-25
US08/591,318 US5776925A (en) 1996-01-25 1996-01-25 Methods for cancer chemosensitization

Publications (1)

Publication Number Publication Date
KR19990082024A true KR19990082024A (ko) 1999-11-15

Family

ID=24366012

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019980705744A Ceased KR19990082024A (ko) 1996-01-25 1997-01-23 암 화학민감화에서 화학요법제와 함께 사용하기 위한 약제 제조에서의 텍사피린의 용도

Country Status (13)

Country Link
US (1) US5776925A (https=)
EP (1) EP0912196B9 (https=)
JP (1) JP2000503989A (https=)
KR (1) KR19990082024A (https=)
CN (1) CN1093766C (https=)
AT (1) ATE277637T1 (https=)
AU (1) AU715025B2 (https=)
DE (1) DE69730961T2 (https=)
ES (1) ES2227671T3 (https=)
IL (1) IL125459A0 (https=)
NO (1) NO983429L (https=)
NZ (1) NZ331513A (https=)
WO (1) WO1997026915A1 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US6200547B1 (en) * 1994-01-26 2001-03-13 Ferx Incorporated Magnetically responsive compositions for carrying biologically active substances and methods of production and use
US6482436B1 (en) 1993-01-29 2002-11-19 Ferx Incorporated Magnetically responsive composition
US5969111A (en) * 1994-04-14 1999-10-19 Board Of Regents, The University Of Texas System Texaphyrins substituted with imidazole are provided
RU2106146C1 (ru) 1995-07-17 1998-03-10 Институт элементоорганических соединений РАН Средство для подавления опухолевого роста
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
JPH10279502A (ja) * 1997-03-31 1998-10-20 Katsuro Tachibana 光感受性物質の励起方法
US6022526A (en) * 1997-07-30 2000-02-08 Pharmacyclics, Inc. Use of texaphyrins in detection of melanin and melanin metabolites diagnostic of melanotic melanoma
HK1041209A1 (zh) 1999-01-13 2002-07-05 Meditech Research Limited 加強藥物療效的成份及方法
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
AU1233701A (en) * 1999-10-29 2001-05-14 Board Of Regents, The University Of Texas System Methods and compositions for treating atheroma, tumors and other neoplastic tissue
US20030031676A1 (en) * 1999-10-29 2003-02-13 Pharmacyclics, Inc. Conjugate compounds for treating atheroma and other diseases
US7579338B2 (en) * 1999-10-29 2009-08-25 Pharmacyclics, Inc. Methods and compositions for treating atheroma, tumors and other neoplastic tissues
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US6638924B2 (en) 2000-08-30 2003-10-28 Pharmacyclics, Inc. Metallotexaphyrin derivatives
US7112671B2 (en) * 2000-08-30 2006-09-26 Pharmacyclics, Inc. Non-symmetric tripyrranes in the synthesis of novel macrocycles
US7449454B2 (en) * 2000-08-30 2008-11-11 Pharmacyclics, Inc. Metallotexaphyrin derivatives
US20030188326A1 (en) 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
EP1345606A4 (en) * 2000-11-17 2005-02-09 Pharmacyclics Inc TEXAPHYRINE COORDINATION COMPOUNDS AND THEIR USE
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
US6630454B2 (en) 2001-09-10 2003-10-07 Ramot At Tel-Aviv University Ltd. Method and pharmaceutical composition for the treatment of cancer
AU2000280389A1 (en) 2001-11-02 2003-05-19 Dana-Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective dna repair mechanisms and treatment thereof
DE60229437D1 (de) * 2001-12-13 2008-11-27 Pharmacyclics Inc Verfahren zur beeinflussung neurologischer progression
AU2002351382A1 (en) * 2001-12-13 2003-06-23 Pharmacyclics, Inc. Combination cancer therapy
US6984734B2 (en) 2002-02-26 2006-01-10 Board Of Regents, The University Of Texas System Cyclo[n]pyrroles and methods thereto
US6723750B2 (en) 2002-03-15 2004-04-20 Allergan, Inc. Photodynamic therapy for pre-melanomas
US20030224422A1 (en) * 2002-04-08 2003-12-04 St. Jude Children's Research Hospital, Inc. Pre-and post therapy gene expression profiling to identify drug targets
US20040010218A1 (en) * 2002-07-11 2004-01-15 Henderson Barbara W. Photodynamic therapy for the enhancement of vascular permeability to aid in drug delivery to diseased tissues
JP2004077714A (ja) * 2002-08-15 2004-03-11 Fuji Xerox Co Ltd 光走査装置
US7981928B2 (en) 2002-09-05 2011-07-19 Nanodynamics, Inc. Chemotherapy method using x-rays
WO2005112759A1 (en) * 2004-05-20 2005-12-01 Pharmacyclics, Inc. A method of enhancing visualization of atherosclerotic plaque
JP2006224318A (ja) * 2005-02-15 2006-08-31 Brother Ind Ltd インクジェット記録装置
JP4972929B2 (ja) * 2005-03-25 2012-07-11 ニプロ株式会社 放射線増感剤
EP1704870A1 (en) 2005-03-25 2006-09-27 Nipro Corporation Use of iron compounds as radiosensitizers
CA2616607C (en) * 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
US8319625B2 (en) * 2005-09-01 2012-11-27 Simplexgrinnell Lp Fire alarm textual notification related application
EA013877B1 (ru) * 2005-09-07 2010-08-30 Алкемиа Онколоджи Пти Лимитед Терапевтические композиции, содержащие гиалуроновую кислоту и терапевтические антитела, а также способы лечения
US20070072838A1 (en) 2005-09-26 2007-03-29 Pharmacyclics, Inc. High-purity texaphyrin metal complexes
US20070078119A1 (en) * 2005-09-30 2007-04-05 Pharmacyclics, Inc. Storage system for texaphyrin pharmaceutical formulations
US8440625B2 (en) * 2006-06-26 2013-05-14 University Of British Columbia Secreted protein acidic and rich in cysteine (SPARC) as chemotherapeutic sensitizers
US8287839B2 (en) * 2006-12-04 2012-10-16 Brookhaven Science Associates, Llc Carboranylporphyrins and uses thereof
US8444953B2 (en) * 2007-03-22 2013-05-21 Brookhaven Science Associates, Llc Symmetric and asymmetric halogen-containing metallocarboranylporphyrins and uses thereof
US20080279781A1 (en) * 2007-05-10 2008-11-13 Brookhaven Science Associates, Llc Glycosylated Carboranylporphyrins and Uses Thereof
RU2438718C1 (ru) * 2010-06-18 2012-01-10 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения сарком мягких тканей
TWI445696B (zh) 2010-11-29 2014-07-21 Univ Nat Yang Ming 標靶人類胸線核苷酸激酶誘導惡性腫瘤中的ｄｎａ修復毒性
US9662328B2 (en) 2010-11-29 2017-05-30 National Yang-Ming University Targeting human thymidylate kinase induces DNA repair toxicity in malignant tumor cells
KR102412203B1 (ko) 2014-06-11 2022-06-23 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 백금 내성을 극복하는데 이용하기 위한 텍사피린-pt(iv) 접합체 및 조성물
WO2018112040A1 (en) * 2016-12-13 2018-06-21 Health Research, Inc. Near infrared (nir) photodynamic therapy (pdt) in combination with chemotherapy
KR20230067608A (ko) 2020-08-14 2023-05-16 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 망간 화학 요법, 광음향 이미징, 및 광열 요법을 위한 텍사피린 유도체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252720A (en) * 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
US5559207A (en) * 1989-03-06 1996-09-24 Board Of Regents, University Of Texas Texaphyrin metal complex mediated ester hydrolysis
US4935498A (en) * 1989-03-06 1990-06-19 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5599923A (en) * 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
US5607924A (en) * 1992-01-21 1997-03-04 Pharmacyclics, Inc. DNA photocleavage using texaphyrins
US5714328A (en) * 1995-06-07 1998-02-03 Board Of Regents, The University Of Texas System RNA photocleavage using texaphyrins

Also Published As

Publication number Publication date
AU1833397A (en) 1997-08-20
DE69730961T2 (de) 2005-11-24
CN1213313A (zh) 1999-04-07
AU715025B2 (en) 2000-01-13
WO1997026915A1 (en) 1997-07-31
EP0912196B1 (en) 2004-09-29
JP2000503989A (ja) 2000-04-04
ES2227671T3 (es) 2005-04-01
NZ331513A (en) 2001-10-26
IL125459A0 (en) 1999-03-12
HK1018588A1 (en) 1999-12-30
DE69730961D1 (de) 2004-11-04
NO983429L (no) 1998-09-24
US5776925A (en) 1998-07-07
CN1093766C (zh) 2002-11-06
EP0912196B9 (en) 2005-01-05
EP0912196A1 (en) 1999-05-06
NO983429D0 (no) 1998-07-24
ATE277637T1 (de) 2004-10-15

Similar Documents

Publication Publication Date Title
KR19990082024A (ko) 암 화학민감화에서 화학요법제와 함께 사용하기 위한 약제 제조에서의 텍사피린의 용도
US6207660B1 (en) Texaphyrin conjugates and uses thereof
US20230036839A1 (en) Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy
TWI222863B (en) Synergistic pharmaceutical compositions comprising anthracycline derivatives and anticancer agents
AU717193B2 (en) Use of a texaphyrin in photodynamic therapy of pigment-related lesions
JPH10500659A (ja) 改善された官能性を有するテキサフィリン金属錯体
CN112245591A (zh) 化疗药物-低氧激活前药一体化前药自组装纳米粒的构建
CN111135299A (zh) 光敏剂-低氧激活前药一体化前药自组装纳米粒的构建
JPH08502488A (ja) 前立腺癌および初期神経悪性疾患に対するベンゾキノイドアンサマイシンの殺腫瘍活性
EP1345606A2 (en) Texaphyrin coordination compounds and uses thereof
EP2890374B1 (en) Compositions and methods for drug-sensitization or inhibition of a cancer cell
US6638924B2 (en) Metallotexaphyrin derivatives
Saunders et al. The radiosensitizer Ro 03-8799 and the concentrations which may be achieved in human tumours: a preliminary study
US20030087964A1 (en) Method and pharmaceutical composition for the treatment of cancer
KR102906540B1 (ko) 면역항암제가 탑재된 광역학 치료용 약학 조성물 및 이의 용도
CN110590850A (zh) 一种抗急性髓系白血病的化合物及其制备方法与应用
CA2243392C (en) Use of a texaphyrin in the preparation of a medicament for use with a chemotherapeutic agent in cancer chemosensitization
HK1018588B (en) Use of a texaphyrin in the preparation of a medicament for use with a chemotherapeutic agent in cancer chemosensitization
PL229503B1 (pl) Formulacja farmaceutyczna zawierająca izotiocyjaniany i doksorubicynę do zastosowania w leczeniu nowotworów
RU2034562C1 (ru) Способ подавления роста опухолевых клеток и средство для его осуществления
EP4450092A1 (en) Modified oligonucleotide-drug conjugate and use thereof
KR20250090018A (ko) 면역항암제가 결합된 금속-유기 골격체를 포함하는 항암용 조성물 및 이의 용도
US7449454B2 (en) Metallotexaphyrin derivatives
Hammed et al. In Vivo Study of the Anticancer Activity of Doxorubicin Loaded on a Cellulose-Based Nanocarrier System
Furlanut et al. Daunorubicin and daunorubicinol tissue concentrations in gastric cancer patients after local administration of a liposomal preparation

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19980725

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20020123

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20040227

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20041027

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20040227

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I